By Fineline Cube 
AstraZeneca (AZ; NASDAQ: AZN) confirmed the closure of its neuroscience research group during its 2025 Q1 earnings call. Sharon Barr, AstraZeneca’s head of biopharmaceuticals research and development, stated that the decision allows the UK-based pharmaceutical giant to focus more on its “core therapeutic areas.”
Terminated Projects
The terminated projects include MEDI1814 for Alzheimer’s disease, which was in collaboration with Eli Lilly, MEDI0618 for migraine treatment, and MEDI7352 targeting osteoarthritis pain and diabetic neuropathic pain. This marks the complete clearance of AstraZeneca’s neuroscience pipeline, with all research projects in this field now discontinued.-Fineline Info & Tech